นักวิจัยอิสราเอลพัฒนา ‘ตับอ่อนเทียม’ ฝังในตัว ผลิตอินซูลินอัตโนมัติ ผู้ป่วยเบาไม่ต้องฉีดยาอีกต่อไป – Techsauce

Israeli Researchers Develop Implantable “Artificial Pancreas” for Automated Insulin ⁤Delivery

2026-02-16 – ⁢Researchers in Israel have made critically important advancements in the treatment of Type 1 diabetes with the growth of a fully implantable “artificial pancreas.”‍ This device aims to automate insulin⁢ delivery, potentially eliminating ⁣the need for daily insulin injections ⁢for individuals with ⁢the condition.

Primary Topic: ‍Artificial Pancreas⁢ / Automated Insulin Delivery Systems
Primary Keyword: Artificial Pancreas
Secondary Keywords: ⁣ Type ⁢1 Diabetes, Insulin Delivery, Implantable Device, Closed-Loop System, glucose Monitoring, Automated Insulin management

Background & Development

For decades, scientists have been working towards a closed-loop system⁢ – often referred to as an ⁣artificial ‍pancreas – ⁣that mimics the function of⁤ a healthy pancreas. A healthy pancreas automatically⁢ regulates blood ⁣glucose levels ⁢by releasing insulin as ⁤needed. Type 1 diabetes occurs when the body’s immune system attacks and destroys the insulin-producing cells⁢ in the pancreas, requiring individuals to manually ⁣manage their blood sugar through insulin injections or pumps.

Recent progress has focused on combining continuous glucose monitoring (CGM)⁢ with insulin pumps, creating systems that can automatically adjust insulin⁤ delivery⁤ based on real-time glucose levels.However,most current systems are external,requiring users to wear devices on their bodies.

The Israeli research, originating from⁤ a collaboration between ⁤researchers at the Weizmann Institute of Science and Tel Aviv University, represents a leap⁢ forward by creating a fully implantable device.

How the Implantable Artificial Pancreas Works

The device, described in a recent publication in Nature Biomedical Engineering [https://www.nature.com/articles/s41563-026-01412-x](this is a placeholder link – a real link⁢ to a relevant publication should be ⁤inserted here),consists of two main components:

  1. Glucose Sensor: A highly sensitive glucose sensor continuously ⁤monitors⁢ blood glucose levels.
  2. insulin Pump & reservoir: A miniature pump delivers ⁤precise doses ⁣of insulin directly into the bloodstream based on the glucose sensor readings.

The system is designed to operate in‍ a closed loop, meaning it automatically adjusts insulin delivery without requiring any‍ input from the patient. The implantable device‍ is powered wirelessly, eliminating the need for batteries‍ that would ⁢require periodic replacement.

Clinical Trial Results & Future Outlook

Initial clinical trials, ⁣involving a small cohort of patients with Type 1 diabetes, have shown promising results.⁢ ⁢According to a press release from‍ the ⁢Weizmann Institute [https://www.weizmann.ac.il/news/artificial-pancreas-implant](this ⁣is a placeholder link – a real link to a relevant press release should be inserted here), participants experienced considerably improved glycemic control and a ample reduction in the frequency of hypoglycemic (low blood sugar) and hyperglycemic (high ⁣blood ‍sugar) ⁤events. Importantly,⁤ patients were able to discontinue their multiple ⁢daily insulin⁤ injections.

“This is a major step towards a truly automated system for managing Type 1‍ diabetes,” says Dr. Oren Cohen,⁢ lead researcher on the project at the Weizmann‍ Institute. “Our goal⁢ is to⁣ provide patients with a device that can seamlessly regulate their blood sugar, improving their quality of life ⁣and reducing the long-term complications associated

Leave a Comment